Goldman Sachs analyst David Roman raised the firm’s price target on Edwards Lifesciences (EW) to $108 from $104 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Becton Dickinson price target raised to $215 from $210 at Stifel
- Edwards Lifesciences price target raised to $105 from $100 at Stifel
- Edwards Lifesciences price target raised to $94 from $92 at Evercore ISI
- Edwards Lifesciences receives FDA approval for SAPIEN M3 mitral valve system
- Edwards Lifesciences Advances Smart Surgery Monitoring With Completed SMART TRENDS Study